Orchestra BioMed Holdings Inc. (OBIO) Stock Forecast & Price Target
Orchestra BioMed Holdings Inc. · NASDAQ
$3.85+0.04 (+0.92%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Orchestra BioMed Holdings Inc, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $10.00 to $20.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $13.25 sits 244% above the current $3.85. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.46 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Orchestra BioMed Holdings Inc.
As of Jul, 5 of 6 firms rate OBIO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
OBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.43 – $-0.32 · 5 analysts · -4% YoY
Next period, 5 analysts expect Orchestra BioMed Holdings Inc. to earn $-0.38 a share (range $-0.43 – $-0.32), versus $-0.40 a year earlier. Full-year consensus is $-1.50, growing to $-1.46 the year after.
REVENUE · NEXT QUARTER
$111.5K
Range $100.0K – $141.0K · 5 analysts · -87% YoY
Revenue is expected to reach $111.5K (range $100.0K – $141.0K), -87.0% year-over-year. Full-year consensus is $469.7K, rising to $655.4K next year.
Top analysts covering Orchestra BioMed Holdings Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OBIO.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$20.00+418.8% to target
Overall win rate
41%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$10.00+159.4% to target
Overall win rate
34%
+ Follow
#3
Matt Miksic
Barclays
Buy
$13.00+237.2% to target
Coverage
—
+ Follow
#4
KB
Kyle Bauser
B. Riley Securities
Buy
$10.00+159.4% to target
Coverage
—
+ Follow
#5
JJ
Josh Jennings
TD Cowen
Buy
$15.00+289.1% to target
Coverage
—
+ Follow
OBIO stock forecast FAQ
What is OBIO's average 12-month price target?+
The 4 analysts with a live target average $13.25 for Orchestra BioMed Holdings Inc. over the next 12 months, ranging from a $20.00 high to a $10.00 low.
Is OBIO stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for OBIO?+
The Street-high target is $20.00 (Chardan Capital), and the Street-low is $10.00 (B. Riley Securities). The average of all 4 active targets is $13.25.
How many Wall Street analysts cover OBIO?+
6 analysts have an active rating on Orchestra BioMed Holdings Inc., and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering OBIO?+
Among analysts who currently cover OBIO, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $20.00 target.
What is Orchestra BioMed Holdings Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.43 – $-0.32) across 5 analysts. Full-year EPS is projected at $-1.50, rising to $-1.46 the following year.
How much revenue is Orchestra BioMed Holdings Inc. expected to report next quarter?+
Consensus revenue is $111.5K (range $100.0K – $141.0K). Full-year revenue is projected at $469.7K, growing to $655.4K next year.
Have analysts been upgrading or downgrading OBIO lately?+
As of Jul, 5 of 6 firms rate OBIO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
